Restatement of Previously Issued Financial Statements - Schedule of Restatement of Previously Issued Financial Statements - Condensed Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net Income (Loss)	$ 19,786	$ 49,861	$ 35,123	$ 96,825
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			31,473	23,933
Amortization of debt issuance costs			914	905
Stock-based compensation	5,483	6,985	12,737	14,900
Deferred income taxes, net			(2,053)	738
Contingent consideration	1,791	(6,884)	3,026	(9,295)
Noncash interest income			(2,023)	0
Operating lease right of use asset amortization			6,487	2,482
Other			849	276
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			(4,606)	(8,433)
Inventories			(2,508)	(58,106)
Prepaid expenses and other assets			(12,879)	2,402
Other assets			(888)	(406)
Accounts payable			(3,871)	6,322
Accrued expenses			(11,769)	(4,014)
Operating lease Liabilities			(4,544)	(87)
Long-term liabilities			154	392
Total cash provided by operating activities			45,622	68,834
Cash flows from investing activities:
Acquisitions, net of cash acquired			(28,099)	0
Proceeds from maturity of marketable securities held to maturity			102,323	0
Additions to capitalized software costs			(2,075)	(1,875)
Purchases of property, plant and equipment			(16,749)	(52,576)
Other investing activities			0	(17)
Total cash provided by (used in) investing activities			55,400	(54,434)
Cash flows from financing activities:
Proceeds from exercise of stock options			62	463
Payment of tax withholding obligation on vesting of restricted stock			(11,140)	(14,759)
Repayment of Convertible Senior Notes			(9)	(18)
Payment of earnout consideration			(7,298)	0
Proceeds from issuance of common stock, net			(3)	0
Total cash used in financing activities			(18,388)	(14,314)
Effect of exchange rate changes on cash and cash equivalents			(2,436)	(7,388)
Net increase (decrease) in cash and cash equivalents			80,198	(7,302)
Cash, cash equivalents and restricted cash, beginning of period			523,458	603,814
Cash and cash equivalents, end of period	603,656	$ 596,512	603,656	596,512
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			831	21,739
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			5,243	0
Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			7,229
As Previously Reported
Cash flows from operating activities:
Net Income (Loss)	20,064		48,893
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			31,237
Amortization of debt issuance costs			914
Stock-based compensation			12,737
Deferred income taxes, net			(2,196)
Contingent consideration	1,791		3,026
Noncash interest income			(2,023)
Operating lease right of use asset amortization			6,487	(21,457)
Other			574
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			(4,606)
Inventories			(2,508)
Prepaid expenses and other assets			(11,530)
Other assets			(888)
Accounts payable			(3,871)
Accrued expenses			(26,234)
Operating lease Liabilities			(4,544)	23,852
Long-term liabilities			154
Total cash provided by operating activities			45,622	68,834
Cash flows from investing activities:
Acquisitions, net of cash acquired			(28,099)
Proceeds from maturity of marketable securities held to maturity			102,323
Additions to capitalized software costs			(2,075)
Purchases of property, plant and equipment			(16,749)
Other investing activities			0
Total cash provided by (used in) investing activities			55,400
Cash flows from financing activities:
Proceeds from exercise of stock options			62
Payment of tax withholding obligation on vesting of restricted stock			(11,140)
Repayment of Convertible Senior Notes			(9)
Payment of earnout consideration			(7,298)
Proceeds from issuance of common stock, net			(3)
Total cash used in financing activities			(18,388)
Effect of exchange rate changes on cash and cash equivalents			(2,436)
Net increase (decrease) in cash and cash equivalents			80,198
Cash, cash equivalents and restricted cash, beginning of period			523,458
Cash and cash equivalents, end of period	603,656		603,656
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			831
As Previously Reported | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			5,243
As Previously Reported | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			7,229
Revenue Adjustments
Cash flows from operating activities:
Net Income (Loss)	(82)		(13,378)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			0
Amortization of debt issuance costs			0
Stock-based compensation			0
Deferred income taxes, net			262
Contingent consideration	0		0
Noncash interest income			0
Operating lease right of use asset amortization			0
Other			0
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			0
Inventories			0
Prepaid expenses and other assets			(1,349)
Other assets			0
Accounts payable			0
Accrued expenses			14,465
Operating lease Liabilities			0
Long-term liabilities			0
Total cash provided by operating activities			0
Cash flows from investing activities:
Acquisitions, net of cash acquired			0
Proceeds from maturity of marketable securities held to maturity			0
Additions to capitalized software costs			0
Purchases of property, plant and equipment			0
Other investing activities			0
Total cash provided by (used in) investing activities			0
Cash flows from financing activities:
Proceeds from exercise of stock options			0
Payment of tax withholding obligation on vesting of restricted stock			0
Repayment of Convertible Senior Notes			0
Payment of earnout consideration			0
Proceeds from issuance of common stock, net			0
Total cash used in financing activities			0
Effect of exchange rate changes on cash and cash equivalents			0
Net increase (decrease) in cash and cash equivalents			0
Cash, cash equivalents and restricted cash, beginning of period			0
Cash and cash equivalents, end of period	0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			0
Revenue Adjustments | FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			0
Revenue Adjustments | Avitide, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			0
Other Adjustments
Cash flows from operating activities:
Net Income (Loss)	(196)		(392)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			236
Amortization of debt issuance costs			0
Stock-based compensation			0
Deferred income taxes, net			(119)
Contingent consideration	0		0
Noncash interest income			0
Operating lease right of use asset amortization			0	23,939
Other			275
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable			0
Inventories			0
Prepaid expenses and other assets			0
Other assets			0
Accounts payable			0
Accrued expenses			0
Operating lease Liabilities			0	(23,939)
Long-term liabilities			0
Total cash provided by operating activities			0	$ 0
Cash flows from investing activities:
Acquisitions, net of cash acquired			0
Proceeds from maturity of marketable securities held to maturity			0
Additions to capitalized software costs			0
Purchases of property, plant and equipment			0
Other investing activities			0
Total cash provided by (used in) investing activities			0
Cash flows from financing activities:
Proceeds from exercise of stock options			0
Payment of tax withholding obligation on vesting of restricted stock			0
Repayment of Convertible Senior Notes			0
Payment of earnout consideration			0
Proceeds from issuance of common stock, net			0
Total cash used in financing activities			0
Effect of exchange rate changes on cash and cash equivalents			0
Net increase (decrease) in cash and cash equivalents			0
Cash, cash equivalents and restricted cash, beginning of period			0
Cash and cash equivalents, end of period	$ 0		0
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases			0
Fair value of 31,415 shares of common stock issued for the acquisition of FlexBiosys, Inc.			0
Fair value of 42,621 shares of common stock issued for the Avitide, Inc. contingent consideration earnout			$ 0